Evidence map›Paper›PMID 35919233›Full record

ArticleEcancermedicalscience2022

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer.

Mariana Serrano, Jhajaira M Araujo, Cristian Pacheco, Jackeline Macetas, Mariella A Blum, Alfredo Carrato, Eloy Ruiz, Francisco Berrospi, Carlos Luque, Ivan Chavez and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ecancermedicalscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Mariana SerranoDepartamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Jhajaira M AraujoEscuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Lima 15067, Peru.
Cristian PachecoDepartamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Jackeline MacetasDepartamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Mariella A BlumDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alfredo CarratoDepartment of Medical Oncology, Hospital Ramón y Cajal, Madrid 28034, Spain.
Eloy RuizDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Francisco BerrospiDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Carlos LuqueDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Ivan ChavezDepartamento de Cirugía en Abdomen, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Eduardo PayetDepartamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Luis TaxaDepartamento de Patología, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Paola MontenegroDepartamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru.
Instituto Nacional de Enfermedades Neoplásicas · PEHospital Universitario Ramón y Cajal · ESThe University of Texas MD Anderson Cancer Center · USUniversidad Privada San Juan Bautista · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peru; however, there are no prospective trials for adjuvant chemotherapy in GC after curative gastrectomy in this country. The objective of this study was to evaluate the effectiveness of adjuvant chemotherapy in stage II-III gastric cancer patients who underwent D2 gastrectomy. Methods: We included patients with stage II-III gastric cancer who underwent radical gastrectomy and D2 dissection between 2014 and 2016 at our institution. Patients received 3-week cycles of capecitabine (1,000 mg/m Results: In total, 173 patients were included: 100 (57.8%) patients received adjuvant chemotherapy and surgery (AChS) and 73 (42.2%) surgery alone (SA). Three-year disease-free survival (DFS) was higher in the AChS groups (69%) than in the SA group (52.6%) ( Conclusion: These data suggest that adjuvant capecitabine and oxaliplatin reduce the recurrence and mortality in patients with stage II-III gastric cancer who underwent D2 gastrectomy. PS IIIA and IIIB and LNR > 13.1 benefited more from receiving adjuvant chemotherapy and poorly cohesive gastric carcinoma did not significantly reduce the rates of survival.

Indexed as

adjuvant chemotherapygastric cancersurvival

Identifiers

PMID35919233
PMCPMC9300408
OpenAlexW4280502470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.